Tag: Allergic

Posted on

Allergic Sensitization at School Age is a Systemic Low-grade Inflammatory Disorder.

Related Articles

Allergic Sensitization at School Age is a Systemic Low-grade Inflammatory Disorder.

Allergy. 2016 Dec 19;:

Authors: Chawes BL, Stokholm J, Schoos AM, Rahman N, Brix S, Bisgaard H

Abstract
BACKGROUND: Systemic low-grade inflammation has been demonstrated in a range of the frequent noncommunicable diseases (NCDs) proposing a shared mechanism, but is largely unexplored in relation to allergic sensitization. We therefore aimed to investigate the possible association with childhood allergic sensitization.
METHODS: High sensitivity C-reactive protein (hs-CRP), interleukin-1? (IL-1?), IL-6, tumor necrosis factor-? (TNF-?) and chemokine (C-X-C motif) ligand 8 (CXCL8) were measured in plasma at age 6mo (N=214) and 7yrs (N=277) in children from the Copenhagen Prospective Studies on Asthma in Childhood2000 (COPSAC2000 ) birth cohort. Allergic sensitization against common inhalant and food allergens was determined longitudinally at age ½, 1½, 4 and 6yrs by specific-IgE assessments and skin prick tests. Associations between inflammatory biomarkers and sensitization phenotypes were tested with logistic regression and principle component analyses (PCA).
RESULTS: Adjusted for gender, recent infections and a CRP genetic risk-score, hs-CRP at 7yrs was associated with concurrent elevated specific-IgE against any allergen (adjusted OR (aOR) =1.40; 95% CI, 1.14-1.72; p=0.001), aeroallergens (aOR, 1.43; 1.15-1.77; p=0.001), food allergens (aOR, 1.31; 95% CI, 1.02-1.67; p=0.04), sensitization without any clinical allergy symptoms (aOR=1.40; 1.06-1.85; p=0.02), and with similar findings for skin prick tests. The other inflammatory markers were not univariantly associated with sensitization, but multi-parametric PCA suggested a specific inflammatory response among sensitized children. Inflammatory markers at age 6mo were not associated with subsequent development of sensitization phenotypes.
CONCLUSIONS: Elevated hs-CRP is associated with allergic sensitization in school-aged children suggesting systemic low-grade inflammation as a phenotypic characteristic of this early onset NCD. This article is protected by copyright. All rights reserved.

PMID: 27992959 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Association of Allergic Rhinitis and Sinusitis with Childhood Asthma.

Association of Allergic Rhinitis and Sinusitis with Childhood Asthma.

Indian Pediatr. 2016 Nov 5;:

Authors: Kumar S, Singh M, Das RR, Mathew JL, Saxena AK

Abstract
BACKGROUND: To study the point prevalence of allergic rhinitis and sinusitis in childhood asthma and to examine the relationships among them.
METHODS: In 250 children (age <13 y) with mild-to-moderte asthma, allergic rhinitis was diagnosed by clinical plus nasal eosinophilia criteria, and sinusitis was diagnosed clinically plus confirmation by computerized tomography scan.
RESULTS: The point prevalence of allergic rhinitis was 13.6%, and of sinusitis was 2%. On multivariate analysis, allergic rhinitis, sinusitis, and family history were significantly associated with asthma severity.
CONCLUSION: Allergic rhinitis is common in childhood, but sinusitis is rare.

PMID: 27889716 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.

Related Articles

The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.

Pulm Pharmacol Ther. 2016 Nov 2;:

Authors: Baldissera L, Squebola-Cola DM, Calixto MC, Lima-Barbosa AP, Rennó AL, Anhê GF, Condino-Neto A, De Nucci G, Antunes E

Abstract
OBJECTIVES: Activators of soluble guanylyl cyclase (sGC) act preferentially in conditions of enzyme oxidation or haem group removal. This study was designed to investigate the effects of the sGC activator BAY 60-2770 in murine airways inflammation and human eosinophil chemotaxis.
METHODS: C57Bl/6 mice treated or not with BAY 60-2770 (1 mg/kg/day, 14 days) were intranasally challenged with ovalbumin (OVA). At 48 h, bronchoalveolar lavage fluid (BALF) was performed, and circulating blood, bone marrow and lungs were obtained. Human eosinophils purified from peripheral blood were used to evaluate the cell chemotaxis.
RESULTS: OVA-challenge promoted marked increases in eosinophil number in BAL, lung tissue, circulating blood and bone marrow, all of which were significantly reduced by BAY 60-2770. The IL-4 and IL-5 levels in BALF were significantly reduced by BAY 60-2770. Increased protein expression of iNOS, along with decreases of expression of sGC (?1 and ?1 subunits) and cGMP levels were detected in lung tissue of OVA-challenged mice. BAY 60-2770 fully restored to baseline the iNOS and sGC subunit expressions, and cGMP levels. In human isolated eosinophils, BAY 60-2770 (1-5 ?M) had no effects on the cGMP levels and eotaxin-induced chemotaxis; however, prior incubation with ODQ (10 ?M) markedly elevated the BAY 60-2770-induced cyclic GMP production, further inhibiting the eosinophil chemotaxis.
CONCLUSIONS: BAY 60-2770 reduces airway eosinophilic inflammation and rescue the sGC levels. In human eosinophils under oxidized conditions, BAY 60-2770 elevates the cGMP levels causing cell chemotaxis inhibition. BAY 60-2770 may reveal a novel therapeutic target for asthma treatment.

PMID: 27816773 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Evaluation of Tolerability and Safety of “Allergovac Poliplus” in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice

Conditions:   Allergic Rhinitis;   Rhinoconjunctivitis;   Asthma
Intervention:   Biological: Allergovac Poliplus
Sponsor:   BIAL Industrial Farmacéutica S.A.
Not yet recruiting – verified July 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

Abietic acid attenuates allergic airway inflammation in a mouse allergic asthma model.

Abietic acid attenuates allergic airway inflammation in a mouse allergic asthma model.

Int Immunopharmacol. 2016 Jun 16;38:261-266

Authors: Gao Y, Zhaoyu L, Xiangming F, Chunyi L, Jiayu P, Lu S, Jitao C, Liangcai C, Jifang L

Abstract
Abietic acid (AA), one of the terpenoids isolated from Pimenta racemosa var. grissea, has been reported to have anti-inflammatory and immunomodulatory effects. However, the anti-allergic effects of AA remain unclear. The aim of this study was to investigate the anti-allergic effects of AA in an ovalbumin (OVA)-induced asthma murine model. The model of mouse asthma was established by induction of OVA. AA (10, 20, 40mg/kg) was administered by oral gavage 1h after the OVA treatment on days 21 to 23. At 24h after the last challenge, bronchoalveolar lavage fluid (BALF) and lung tissues were collected to assess pathological changes, cytokines production, and NF-?B expression. The results showed that AA attenuated lung histopathologic changes, inflammatory cells infiltration, and bronchial hyper-responsiveness. AA also inhibited OVA-induced the nitric oxide (NO), IL-4, IL-5, IL-13, and OVA-specific IgE production, as well as NF-?B activation. In conclusion, the current study demonstrated that AA exhibited protective effects against OVA-induced allergic asthma in mice and the possible mechanism was involved in inhibiting NF-?B activation.

PMID: 27318791 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Break for allergic asthma sufferers as ‘lifesaving’ drug subsidised – Herald Sun


Herald Sun

Break for allergic asthma sufferers as 'lifesaving' drug subsidised
Herald Sun
The Coalition will spend $5.4 million to make Omalizumab — an injectable medication used to treat severe asthma not controlled by corticosteroid inhalers — available to hundreds of patients across Australia. The drug is used to treat people who …

and more »

View full post on asthma – Google News

Posted on

House dust mite immunotherapy in adults with allergic asthma – Pharmacy Today, American Pharmacists Association, pharmacist.com


Medscape

House dust mite immunotherapy in adults with allergic asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com
Taking house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablets in addition to maintenance medications appears to help reduce the risk of an attack in people with HDM allergy–related asthma. The double-blind, randomized study was …
HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbationNews-Medical.net
Sublingual Immunotherapy Improves Dust Mite AllergyMedscape

all 6 news articles »

View full post on asthma – Google News

Posted on

Boy Who Died From Asthma or Allergies at School Was Not Given Epi, Had Expired Inhaler – Allergic Living


Allergic Living

Boy Who Died From Asthma or Allergies at School Was Not Given Epi, Had Expired Inhaler
Allergic Living
A 10-year-old Ontario boy with asthma and food allergies, who died after collapsing in his school's office, was without proper asthma controller medication and didn't have epinephrine administered quickly enough, even though he was carrying an …

View full post on asthma – Google News